Jacobson Pharma Corporation Limited

SEHK:2633 Stock Report

Market Cap: HK$1.2b

Jacobson Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jacobson Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth10.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21
Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27
Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20
These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28
Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jul 14
Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Feb 09
Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Nov 29
Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Sep 24
Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16
Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03
Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11
Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27
Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12
Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03
Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jacobson Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2633 - Analysts future estimates and past financials data (HKD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20241,468186355484N/A
12/31/20231,811221N/AN/AN/A
9/30/20231,919217485598N/A
6/30/20231,852234526614N/A
3/31/20231,268175567630N/A
12/31/20221,489207466517N/A
9/30/20221,427203364403N/A
6/30/20221,511190354405N/A
3/31/20221,596178343407N/A
12/31/20211,548166N/AN/AN/A
9/30/20211,501154427490N/A
6/30/20211,473164386450N/A
3/31/20211,446174346409N/A
12/31/20201,478183N/AN/AN/A
9/30/20201,510191257335N/A
6/30/20201,541203267348N/A
3/31/20201,571214277361N/A
9/30/20191,419273523444N/A
6/30/20191,449259437420N/A
3/31/20191,478245352396N/A
12/31/20181,663235259361N/A
9/30/20181,622219166326N/A
6/30/20181,585211161284N/A
3/31/20181,549202156243N/A
12/31/20171,486202N/A217N/A
9/30/20171,424203N/A190N/A
6/30/20171,340191N/A177N/A
3/31/20171,256179N/A164N/A
12/31/20161,188142N/A177N/A
9/30/20161,141142N/A230N/A
6/30/20161,112144N/A226N/A
3/31/20161,084146N/A221N/A
12/31/20151,043145N/A220N/A
3/31/2015948102N/A162N/A
3/31/2014926172N/A150N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2633's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if 2633's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2633's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2633's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2633's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 2633's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.